Clinerion Expands in Georgia
The Medison network of clinics, Tbilisi, Georgia, has joined Clinerion’s Patient Network Explorer platform, bringing their patients access to treatments and therapies.
Patients at Medison’s network of clinics will gain access to treatments and therapies by being matched to international clinical trials.
The Medison network of clinics specializes in outpatient and dental services for all social strata. The four clinics in Tbilisi, Georgia, provide medical care to over 6,000 patients each month.
The network has specialist clinical staff and is fully equipped for clinical trials. Medison currently has several trials running.
“We are very happy to have the opportunity to support more patients in Georgia via partnership with Medison,”says Ian Rentsch, CEO of Clinerion. “We look forward to drawing more trials to the country.”
Learn more at www.clinerion.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
